Takeda touts late-breaking Phase 3 data for TAK-921 in advanced gastric cancer at ESMO 2026

PUBT · 1d ago
Takeda touts late-breaking Phase 3 data for TAK-921 in advanced gastric cancer at ESMO 2026
  • Takeda flagged late-breaking Phase 3 data for arcotatug tavatecan (TAK-921) for presentation at ESMO 2026 on Oct. 23.
  • The study in previously treated advanced gastric or gastroesophageal junction cancer showed outcomes that could support a Japan regulatory filing.
  • Two additional ESMO 2026 presentations will outline updated findings for TAK-928 in immunotherapy-resistant NSCLC and in first-line NSCLC.
  • A global Phase 3 trial, MarsLight-11, is enrolling to test TAK-928 against docetaxel in progressed squamous NSCLC.
  • The trial will be expanded to add a sub-study in non-squamous NSCLC, broadening the program’s commercial addressable population.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260921356638) on September 22, 2026, and is solely responsible for the information contained therein.